Acute Leukemias - Republican Scientific Medical Library
Acute Leukemias - Republican Scientific Medical Library
Acute Leukemias - Republican Scientific Medical Library
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
a References 259<br />
ministered and the clinical context in which it is being<br />
evaluated. Prospective MRD monitoring may enhance<br />
our ability to interpret the efficacy of these new treatment<br />
strategies. Only by addressing these issues using<br />
standardized methods for MRD evaluation will the clinical<br />
promise of this important bio-marker be realized.<br />
References<br />
1. Miller CB, et al. (1991) Correlation of occult clonogenic leukemia<br />
drug sensitivity with relapse after autologous bone marrow transplantation.<br />
Blood 78(4):1125–1131<br />
2. Potter MN, et al. (1993) Molecular evidence of minimal residual<br />
disease after treatment for leukaemia and lymphoma: An updated<br />
meeting report and review. Leukemia 7(8):1302–1314<br />
3. Pui CH, Campana D (2000) New definition of remission in childhood<br />
acute lymphoblastic leukemia. Leukemia 14(5):783–785<br />
4. Campana D, Pui CH (1995) Detection of minimal residual disease<br />
in acute leukemia: Methodologic advances and clinical significance.<br />
Blood 85(6):1416–1434<br />
5. Szczepanski T, et al. (2001) Minimal residual disease in leukaemia<br />
patients. Lancet Oncol 2(7):409–417<br />
6. Vidriales MB, et al. (2003) Minimal residual disease monitoring by<br />
flow cytometry. Best Pract Res Clin Haematol 16(4):599–612<br />
7. Campana D, Coustan-Smith E (2002) Advances in the immunological<br />
monitoring of childhood acute lymphoblastic leukaemia.<br />
Best Pract Res Clin Haematol 15(1):1–19<br />
8. Coustan-Smith E, et al. (1998) Immunological detection of minimal<br />
residual disease in children with acute lymphoblastic leukaemia.<br />
Lancet 351(9102):550–554<br />
9. Inoue K, et al. (1994) WT1 as a new prognostic factor and a new<br />
marker for the detection of minimal residual disease in acute leukemia.<br />
Blood 84(9):3071–3079<br />
10. Inoue K, et al. (1997) Aberrant overexpression of the Wilms tumor<br />
gene (WT1) in human leukemia. Blood 89(4):1405–1412<br />
11. Miyagi T, et al. (1993) Expression of the candidate Wilm’s tumor<br />
gene, WT1, in human leukemia cells. Leukemia 7(7):970–977<br />
12. Bergmann L, et al. (1997) High levels of Wilms‘ tumor gene (wt1)<br />
mRNA in acute myeloid leukemias are associated with a worse<br />
long-term outcome. Blood 90(3):1217–1225<br />
13. Sugiyama H (1998) Wilms tumor gene (WT1) as a new marker for<br />
the detection of minimal residual disease in leukemia. Leuk Lymphoma<br />
30(1–2):55–61<br />
14. Miwa H, Beran M, Saunders GF (1992) Expression of the Wilms‘<br />
tumor gene (WT1) in human leukemias. Leukemia 6(5):405–409<br />
15. Menssen HD, et al. (1995) Presence of Wilms‘ tumor gene (wt1)<br />
transcripts and the WT1 nuclear protein in the majority of human<br />
acute leukemias. Leukemia 9(6):1060–1067<br />
16. Inoue K, et al. (1996) Long-term follow-up of minimal residual disease<br />
in leukemia patients by monitoring WT1 (Wilms tumor gene)<br />
expression levels. Blood 88(6):2267–2278<br />
17. Tamaki H, et al. (1996) Increased expression of the Wilms tumor<br />
gene (WT1) at relapse in acute leukemia. Blood 88(11):4396–4398<br />
18. Ogawa H, et al. (2003) The usefulness of monitoring WT1 gene<br />
transcripts for the prediction and management of relapse follow-<br />
ing allogeneic stem cell transplantation in acute type leukemia.<br />
Blood 101(5):1698–1704<br />
19. Garg M, et al. (2003) Prognostic significance of quantitative analysis<br />
of WT1 gene transcripts by competitive reverse transcription<br />
polymerase chain reaction in acute leukaemia. Br J Haematol<br />
123(1):49–59<br />
20. Cilloni D, et al. (2002) Quantitative assessment of WT1 expression<br />
by real time quantitative PCR may be a useful tool for monitoring<br />
minimal residual disease in acute leukemia patients. Leukemia<br />
16(10):2115–2121<br />
21. Kreuzer KA, et al. (2001) Fluorescent 5‘-exonuclease assay for the<br />
absolute quantification of Wilms‘ tumour gene (WT1) mRNA: Implications<br />
for monitoring human leukaemias. Br J Haematol<br />
114(2):313–318<br />
22. Pongers-Willemse MJ, et al. (1999) Primers and protocols for standardized<br />
detection of minimal residual disease in acute lymphoblastic<br />
leukemia using immunoglobulin and T cell receptor gene<br />
rearrangements and TAL1 deletions as PCR targets: Report of the<br />
BIOMED-1 CONCERTED ACTION: Investigation of minimal residual<br />
disease in acute leukemia. Leukemia 13(1):110–118<br />
23. van Dongen JJ, Wolvers-Tettero IL (1991) Analysis of immunoglobulin<br />
and T cell receptor genes. Part II: Possibilities and limitations<br />
in the diagnosis and management of lymphoproliferative diseases<br />
and related disorders. Clin Chim Acta 198(1–2):93–174<br />
24. van Dongen JJ, et al. (1999) Standardized RT-PCR analysis of fusion<br />
gene transcripts from chromosome aberrations in acute leukemia<br />
for detection of minimal residual disease. Report of the<br />
BIOMED-1 Concerted Action: Investigation of minimal residual<br />
disease in acute leukemia. Leukemia 13(12):1901–1928<br />
25. Hunger SP (1996) Chromosomal translocations involving the E2A<br />
gene in acute lymphoblastic leukemia: Clinical features and molecular<br />
pathogenesis. Blood 87(4):1211–1224<br />
26. Hunger SP, et al. (1998) E2A-PBX1 chimeric transcript status at end<br />
of consolidation is not predictive of treatment outcome in childhood<br />
acute lymphoblastic leukemias with a t(1;19)(q23;p13): A Pediatric<br />
Oncology Group study. Blood 91(3):1021–1028<br />
27. Privitera E, et al. (1992) Different molecular consequences of the<br />
1;19 chromosomal translocation in childhood B-cell precursor<br />
acute lymphoblastic leukemia. Blood 79(7):1781–1788<br />
28. Devaraj PE, et al. (1995) Expression of the E2A-PBX1fusion transcripts<br />
in t(1;19)(q23;p13) and der(19)t(1;19) at diagnosis and in<br />
remission of acute lymphoblastic leukemia with different B lineage<br />
immunophenotypes. Leukemia 9(5):821–825<br />
29. Lanza C, et al. (1996) Persistence of E2A/PBX1 transcripts in t(1;19)<br />
childhood acute lymphoblastic leukemia: Correlation with chemotherapy<br />
intensity and clinical outcome. Leuk Res 20(5):441–443<br />
30. Group Francais de Cytogenetique Hematologique (1996) Cytogenetic<br />
abnormalities in adult acute lymphoblastic leukemia: Correlations<br />
with hematologic findings outcome. A Collaborative Study<br />
of the Group Francais de Cytogenetique Hematologique. Blood<br />
87(8):3135–3142<br />
31. Gabert J, et al. (2001) Improved outcome of Adult patients with<br />
E2A PBX1/t(1;19) positive ALL after intensive therapy: Results of<br />
the LAL-94 multicentric protocol. Blood 98:840a<br />
32. Secker-Walker LM, et al. (1997) Cytogenetics adds independent<br />
prognostic information in adults with acute lymphoblastic leukaemia<br />
on MRC trial UKALL XA. MRC Adult Leukaemia Working Party.<br />
Br J Haematol 96(3):601–610